Molecular Templates, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters
  • Pipeline
    • Overview
    • MT-3724
    • MT-5111
    • TAK-169
  • Clinical Trials
    • Overview
    • MT-3724 With Lenalidomide for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-3724 for Relapsed or Refractory DLBCL Active, not recruiting
    • MT-3724 With Gemcitabine and Oxaliplatin for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-5111 in HER2-positive Solid Tumors Recruiting
    • TAK-169 for Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Contact
  • Careers

Quote

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Email Alerts

  • Stock Data

  • Quote
  • Charts
  • Historical Data
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2021 Molecular Templates, Inc. All Rights Reserved.
Twitter Linkedin
Privacy Policy Disclaimer Terms of Use Sitemap

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.